Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

1 september 2026 uppdaterad av: PleoPharma, Inc.

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Clinical Trial of Titrating Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder: Core Study With Safety Extension Phase

This study is a randomized, double-blind, placebo and active-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to severe cannabis use disorder (CUD). Study participants will receive PP-01, nabilone, or placebo every day for 34 days. The total study duration will be approximately 78 days, including screening and a one-week inpatient stay. Following the initial inpatient portion of the study, participants will return to the clinic for six clinic visits and complete two telemedicine appointments. Participants will complete daily symptom diaries and other study-related questionnaires.

Participants who complete the core study may be eligible to participate in a repeat dosing extension study if they meet required criteria.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

420

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

  • Förenta staterna
    • Arkansas
      • Little Rock, Arkansas, Förenta staterna, 72211
        • Rekrytering
        • Woodland International Research Group, LLC
        • Huvudutredare:
          • George Konis, MD
      • Rogers, Arkansas, Förenta staterna, 72758
        • Rekrytering
        • Woodland Research Northwest, LLC
        • Huvudutredare:
          • Ryan Mahelona, MD
    • Connecticut
      • New Haven, Connecticut, Förenta staterna, 06519
        • Rekrytering
        • Yale Stress Center
        • Huvudutredare:
          • Rajita Sinha, PhD
    • Florida
      • DeLand, Florida, Förenta staterna, 32720
        • Rekrytering
        • University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit
        • Huvudutredare:
          • Bruce G. Rankin, DO
      • Hollywood, Florida, Förenta staterna, 33024
        • Rekrytering
        • Research Centers of America
        • Huvudutredare:
          • Edwin A. Gomez, MD
      • Largo, Florida, Förenta staterna, 33777
        • Rekrytering
        • Sandhill Research, LLC d/b/a Accel Research Sites - St. Pete - Largo Clinical Research Unit
        • Huvudutredare:
          • Rosario B. Hidalgo, MD
      • Tampa, Florida, Förenta staterna, 33613
        • Rekrytering
        • ForCare Clinical Research
        • Huvudutredare:
          • Marlene P. Hart, MD
      • West Palm Beach, Florida, Förenta staterna, 33407
        • Rekrytering
        • Neuroscience Research Institute
        • Huvudutredare:
          • Danesh Alam, MD
    • Georgia
      • Decatur, Georgia, Förenta staterna, 30030
        • Rekrytering
        • Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies Clinical Research Unit 755
        • Huvudutredare:
          • Marshall L. Nash, MD, FAHA, CPI, FAPCR
      • Norcross, Georgia, Förenta staterna, 30092
        • Rekrytering
        • Evergreen Clinical Trials
        • Huvudutredare:
          • Dmitriy Pelishev, DO
      • Savannah, Georgia, Förenta staterna, 31405
        • Rekrytering
        • CenExel iResearch, LLC
        • Huvudutredare:
          • Nancy E. Backus, MD
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40509
        • Rekrytering
        • AMR Clinical
        • Huvudutredare:
          • Peter Akpunonu, MD
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21228
        • Rekrytering
        • Maryland Psychiatric Research Center, University of Maryland School of Medicine
        • Huvudutredare:
          • David A Gorelick, MD, PhD
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89121
        • Rekrytering
        • Oasis Clinical Research
        • Huvudutredare:
          • Stephen Tam, MD
    • New Jersey
      • Marlton, New Jersey, Förenta staterna, 08053
        • Rekrytering
        • Hassman Research Institute, LLC d/b/a CenExel Marlton, NJ
        • Huvudutredare:
          • Elan A. Cohen, PhD
    • New York
      • New York, New York, Förenta staterna, 10032
        • Rekrytering
        • The Research Foundation for Mental Hygiene/ New York State Psychiatric Institute
        • Huvudutredare:
          • John Mariani, MD
      • Staten Island, New York, Förenta staterna, 10314
        • Rekrytering
        • Richmond Behavioral Associates
        • Huvudutredare:
          • Romana Kulikova, MD
    • Ohio
      • North Canton, Ohio, Förenta staterna, 44720
        • Rekrytering
        • Neuro-Behavioral Clinical Research, Inc.
        • Huvudutredare:
          • Shishuka Malhotra, MD
    • South Carolina
      • North Charleston, South Carolina, Förenta staterna, 29405
        • Rekrytering
        • Coastal Carolina Research Center, LLC
        • Huvudutredare:
          • Elizabeth Perkins, MD
    • Tennessee
      • Knoxville, Tennessee, Förenta staterna, 37920
        • Rekrytering
        • AMR Clinical
        • Huvudutredare:
          • Jerry L. Punch, MD
    • Texas
      • Austin, Texas, Förenta staterna, 78754
        • Rekrytering
        • Community Clinical Research, Inc.
        • Huvudutredare:
          • David Brown, MD
      • Houston, Texas, Förenta staterna, 77043
        • Rekrytering
        • Memorial Hermann Village
        • Huvudutredare:
          • Dominick Stevan D'Aunno, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Generally healthy adults between the ages of 18 and 55, inclusive.
  2. Meet DSM-5 diagnostic criteria for current moderate to severe CUD as confirmed by a licensed physician or psychologist or addiction medicine specialist.
  3. BMI within 18.0 to 38.0 kg/m2, inclusive.
  4. Female participants must not be pregnant or lactating. If of childbearing potential - the participant agrees to use an accepted contraceptive regimen.
  5. Male participants who are fertile and engage in sexual activity must agree to use a double barrier method (e.g., condom and spermicide) during the study and to not donate sperm for 90 days after the last dose of study medication.
  6. Be seeking and motivated to discontinue cannabis and to minimize withdrawal symptoms.
  7. Agree to not use cannabis or any product containing CBD, hemp derivatives, terpenes or any THC containing product including delta-8, delta-10, THC-A or any other cannabinoid-like product following Randomization and throughout the study duration.
  8. Meet DSM-5 Cannabis Withdrawal Criteria.
  9. Report heavy use of daily/near daily cannabis.
  10. Have a urine drug screen positive for THC/THC metabolite and have a negative result for all other illicit/excluded drugs and alcohol at Screening and Randomization.
  11. Capable of giving informed consent and stated willingness to comply with all study procedures including inpatient and weekly outpatient visits, daily evening video calls, restrictions, and availability for the duration of the study.
  12. Willing to be admitted to an inpatient clinic with overnight stays on Days 1 through 6 and return for all outpatient visits.
  13. Ability to take study drug capsules at approximately the same time each day.
  14. Have regular access to the internet and access to video/virtual capabilities for video calls by any means.
  15. Agree to not use any alcohol during the study.
  16. No plan to change current nicotine use.
  17. Ability to read, understand, and complete daily diaries.

Exclusion Criteria:

  1. Lifetime history of DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.
  2. Current DSM-5 criteria for a psychiatric disorder that in the Investigator's judgment is unstable, would be disrupted by the study medication, or is likely to require new pharmacotherapy or psychotherapy during the study period. Individuals who are currently stable on psychotropic medication for at least 3 months may be included at the discretion of the Investigator's judgement.
  3. Participants who meet DSM-5 criteria for any history of or current drug use disorder within the previous 2 years, other than cannabis, nicotine, or caffeine use disorders.
  4. Participants who consume alcohol on a regular or frequent basis and who do not agree or are deemed by the Investigator to be unable to discontinue alcohol for the duration of the study.
  5. Participants using cannabis for a physician directed medical condition requiring use such as epilepsy.
  6. Any clinically important abnormalities on Screening physical examination, assessments, electrocardiogram, or laboratory tests.
  7. Current or recent history of significant violent or suicidal behavior, risk for suicide or homicide.
  8. History of clinically significant medical condition that, in the opinion of the Principal Investigator, would jeopardize the safety of the participant or impact on the validity of the study results.
  9. Participants with risk factors for seizure.
  10. Known history of allergy, intolerance, or hypersensitivity to nabilone, gabapentin, or pregabalin.

  11. Prohibited medications at Screening:

    • Current use of narcotics, psychedelics, stimulants, opioid agonists and antagonists, kratom, illicit drugs, ketamine, unregulated psychoactive drugs (sometimes known as "gas station drugs"), or products intended to induce a feeling of being high except for cannabis
    • Regular benzodiazepine use (more than once per week) and no use within 7 days of Baseline Visit (Day 1)
    • Current use (within 7 days of Baseline Visit) of OTC products to help with sleep or anxiety
    • Prescription medications to help with sleep or anxiety within 14 days of Screening
    • Current use of nabilone, dronabinol, Sativex, Epidiolex, synthetic cannabinoids
    • Gabapentin or pregabalin or use within 30 days of Screening
  12. Heavy users of alcohol within 60 days of Screening or binge drinkers of alcohol within 30 days of Screening.
  13. A positive urine drug/alcohol test at Screening or Randomization for narcotics and/or illicit drugs other than cannabis. If the test is positive for benzodiazepines or alcohol at Screening, and if it is reported that they are only occasional users, a repeat urine drug screen can be performed at the discretion of the Medical Monitor and must be negative at the time of Randomization.
  14. Use of an investigational drug or biologic within 30 days or 5 times the half-life (whichever is longer) prior to the Screening Visit.
  15. Active influenza or COVID-19 infection or planned vaccination.
  16. Prior participation in any PleoPharma clinical study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: PP-01
Oral PP-01 tapered/titrated over 34 days
Kombinationsprodukt: PP-01
Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
Aktiv komparator: Nabilone
Oral Nabilone tapered/titrated over 34 days
Läkemedel: Nabilone
CB1 partial agonist
Placebo-jämförare: Placebo
Oral Placebo given daily for 34 days
Läkemedel: Placebo
Placebo-jämförare

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
AUCs of the CSCW over Days 2 to 7, inclusive, comparing PP-01 vs Placebo
Tidsram: Days to 2 to 7
Days to 2 to 7
AUCs of the CSCW over Days 25 to 35, inclusive, comparing PP-01 vs Nabilone to assess rebound
Tidsram: Days 25 to 35
Days 25 to 35

Sekundära resultatmått

Resultatmått
Tidsram
AUCs of CWS-20 Irritability Domain scores over Days 2 to 35 comparing PP-01 vs Placebo
Tidsram: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Irritability Domain scores over Days 25 to 35 comparing PP-01 vs Nabilone
Tidsram: Days 25 to 35
Days 25 to 35
AUCs of the CSCW over Days 2 to 35 comparing PP-01 vs Placebo
Tidsram: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Sleep Domain scores over Days 2 to 35 comparing PP-01 vs Placebo
Tidsram: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Sleep Domain scores over Days 2 to 7 comparing PP-01 vs Placebo
Tidsram: Days 2 to 7
Days 2 to 7
AUCs of CWS-20 Craving Domain scores over Days 2 to 35 comparing PP-01 vs Placebo
Tidsram: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Craving Domain scores over Days 2 to 7 comparing PP-01 vs Placebo
Tidsram: Days 2 to 7
Days 2 to 7

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

PleoPharma, Inc.

Utredare

  • Studierektor: Jay Constantine, MD, PleoPharma, Inc.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

17 juni 2026

Primärt slutförande (Beräknad)

1 juni 2027

Avslutad studie (Beräknad)

1 september 2027

Studieregistreringsdatum

Först inskickad

8 juni 2026

Först inskickad som uppfyllde QC-kriterierna

8 juni 2026

Första postat (Faktisk)

12 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • CAN-004

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera